Compare Eli Lilly And Co (LLY) vs Sea Limited (SE) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Sea Limited (SE) trades at $106.00, up 1.87% on the day, with a bearish technical signal despite bullish moving averages. The company reported strong revenue growth, with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent quarterly earnings have been mixed. Positive cash flow trends and a robust analyst consensus with a $131.00 price target highlight fundamental strength, but insider selling and competitive pressures present headwinds.

The outlook for SE is cautiously optimistic, driven by sustained revenue expansion and improving profitability. Key risks include execution challenges in its e-commerce and gaming segments, geopolitical tensions affecting operations, and insider selling activity. The stock's valuation multiples suggest growth expectations are priced in, requiring continued strong performance to justify further upside.